Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 12, 2024

Primary Completion Date

October 14, 2026

Study Completion Date

December 31, 2026

Conditions
Type 2 Diabetes
Interventions
DIETARY_SUPPLEMENT

Lactobacillus paracasei LC19 supplementation

Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).

DIETARY_SUPPLEMENT

Placebo probiotic milk powder

Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).

Trial Locations (1)

100020

RECRUITING

Beijing Chao-yang Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Chao Yang Hospital

OTHER